dual A2aR checkpoint inhibitor/CD73 checkpoint inhibitor (Ex scientia/Evotec)

N/A

Report date: 2025/03/19 08:56:50
NME

Base Information

Drug Namedual A2aR checkpoint inhibitor/CD73 checkpoint inhibitor (Ex scientia/Evotec)
Drug Alias Nameadenosine 2A receptor/CD73 bispecific small molecule antagonists (Ex scientia/Evotec)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAdenosine A2a receptor antagonists5'-nucleotidase inhibitors
Targets5'-nucleotidaseAdenosine A2a receptor
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermanyUnited Kingdom
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesRecursion Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesRecursion Pharmaceuticals IncEvotec SE
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A